04:24 PM EST, 01/09/2025 (MT Newswires) -- IO Biotech ( IOBT ) said Thursday it completed enrollment ahead of schedule in a phase 2 trial of its cancer vaccine candidate IO102-IO103 combined with Merck's ( MRK ) Keytruda to treat people with resectable melanoma or squamous cell carcinoma of the head and neck.

Initial data is expected this year, the company said.

The trial has enrolled 93 people in the US, Europe and Australia, the company added.